By Julie Steenhuysen June 06, 2023 CHICAGO (Reuters) – Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread by 65% over treatment with an immunotherapy alone in a mid-stage trial, the companies reported on Monday. With this and earlier data, Moderna is considering...